Shares of Regeneron Pharmaceuticals Inc. REGN, +0.07% gained about 2.5% in premarket trading on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Dupixent, the atopic dermatitis therapy developed with Sanofi SAN, -0.19% SNY, -0.66%, for children as young as six months old. European regulators are expected to make a final decision in the coming months. Regeneron’s stock has gained 21.9% over the past year, while the broader S&P 500 SPX, +0.25% is down 6.6%.
This article was originally published by Marketwatch.com. Read the original article here.
